HLA-DR Antibody [L16M22]

Catalog No.: F9538

    Application: Reactivity:
    • Lane 1: Raji, Lane 2: Ramos
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000- 1:10000
    1:100 - 1:1000
    1:250- 1:500
    Application
    WB, IHC, IF
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    29 kDa 37 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    HLA-DR Antibody [L16M22] detects endogenous levels of total HLA-DR protein.
    Clone
    L16M22
    Synonym(s)
    HLA-DRA1, HLA-DRA, MHC class II antigen DRA
    Background
    HLA‑DR is a heterodimeric class II major histocompatibility complex receptor composed of an invariant DRα chain and a polymorphic DRβ chain that localizes to the surface of professional antigen‑presenting cells and mediates presentation of exogenous and selected endogenous peptides to CD4 T cells, placing it at the core of adaptive immune initiation and regulation. The extracellular portion of each chain contains two Ig‑like domains that pair to form an open‑ended peptide‑binding groove supported by a β‑sheet floor and flanking α‑helices, with key peptide contact residues concentrated in the N‑terminal portions of both chains and specificity largely dictated by polymorphic positions in DRβ. Peptides of roughly 10–30 residues generated from endocytosed proteins in late endosomes and lysosomes are loaded onto newly synthesized HLA‑DR in specialized MHC class II compartments; an invariant chain initially occupies the groove and targets the complex to the endocytic pathway, where sequential proteolysis leaves CLIP fragments that are exchanged for higher‑affinity peptides under the control of the DM chaperone. The resulting HLA‑DR–peptide complexes traffic to the plasma membrane and engage TCRs on CD4 T cells, providing signal 1 for T‑cell activation, while co‑stimulatory receptors and cytokines supplied by the antigen‑presenting cell determine the differentiation and effector profile of the responding T‑cell population. In peripheral tissues and tumor microenvironments, HLA‑DR presents peptides derived from internalized microbial antigens, self‑proteins, and tumor‑associated proteins taken up by phagocytosis or macropinocytosis, guiding helper T‑cell responses that support antibody production, macrophage activation, and cytotoxic T‑cell priming directed against pathogens or transformed cells. Autophagy‑linked processing routes deliver cytosolic and nuclear proteins to autolysosomes for loading onto HLA‑DR, a mechanism that contributes to positive and negative selection of CD4 T cells in the thymus and to maintenance of central tolerance by presenting a broader self‑peptide repertoire. Expression of HLA‑DR is largely restricted to dendritic cells, macrophages, B cells, and thymic epithelial cells under homeostatic conditions but is inducible on additional cell types under inflammatory stimulation, making surface HLA‑DR a marker of immune activation and antigen‑presenting cell maturation. Extensive polymorphism in HLA‑DRB1 and linked DRB loci shapes the peptide‑binding groove and TCR contact surfaces, creating distinct peptide‑binding motifs that influence susceptibility or resistance to autoimmune diseases, infection outcomes, and responses to vaccines and biologic therapies. HLA‑DR matching between donor and recipient is a major determinant of graft acceptance and long‑term survival in hematopoietic and solid‑organ transplantation, reflecting the strong alloreactive T‑cell responses elicited by mismatched DR–peptide complexes.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください